The purpose of the study is to test whether the addition of an immunotherapy drug, called tislelizumab, to the standard of care treatment of high-risk endometrial cancer reduces the risk of the disease coming back, and to determine if the new course of therapy is well-tolerated by participants.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 2 Drug TrialEarly stage studies investigating efficacy and safety compared to standard therapies, as well as final dose determination in moderate sized patient cohorts.
- Registry listing
-
ERM Project ID
73612
Trial contact details
-
Contact person
Caitlin Bennett
-
Phone
07 3163 7689
What you need to know
Who can take part?
Any patients who have been diagnosed with high-risk endometrial cancer who have received surgery for the condition, and also require radiation and then chemotherapy. This trial can only enrol patients who have surgery in the previous 8 weeks.
What is involved for you?
Patients have standard treatment for their disease, and 2/3 of patients in the trial also receive an additional immunotherapy medication (tislelizumab). Standard of care chemotherapy involves attending the clinic every 3 weeks for chemotherapy for 4 cycles. For patients who are receiving the additional immunotherapy medication (tislelizumab), you will need to continue to attend the clinic for an additional 8 cycles. While in the clinic you will have a physical assessment, blood collection and complete a quality of life survey.
